Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) Operating Expenses (2016 - 2026)

Mimedx's Operating Expenses history spans 16 years, with the latest figure at $57.4 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 9.36% to $57.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $166.3 million, a 8.39% increase, with the full-year FY2025 number at $71.6 million, up 15.75% from a year prior.
  • Operating Expenses hit $57.4 million in Q1 2026 for Mimedx, up from $16.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for MDXG hit a ceiling of $72.7 million in Q3 2025 and a floor of $13.5 million in Q1 2024.
  • Historically, Operating Expenses has averaged $46.0 million across 5 years, with a median of $55.9 million in 2023.
  • Biggest five-year swings in Operating Expenses: plummeted 75.79% in 2024 and later soared 369.11% in 2025.
  • Tracing MDXG's Operating Expenses over 5 years: stood at $45.1 million in 2022, then rose by 25.89% to $56.8 million in 2023, then crashed by 70.11% to $17.0 million in 2024, then fell by 2.2% to $16.6 million in 2025, then surged by 245.59% to $57.4 million in 2026.
  • Business Quant data shows Operating Expenses for MDXG at $57.4 million in Q1 2026, $16.6 million in Q4 2025, and $72.7 million in Q3 2025.